// App-Quantinova.ai

: Determination of the Prognostic Utility of Immunohistochemically Assessed hENT1 Expression in Resected Hilar Cholangiocarcinoma Patients

Researchers

Presenter

  • N. Bird

Principal Investigators

  • N. Manu

  • M. Quinn

  • T. Gill

  • S. Fenwick

  • R. Diaz-Nieto

  • R. Jones

  • H. Malik

Medical Centers

  • University Hospital Aintree, Liverpool, United Kingdom

  • Queen Elizabeth Hospital, Coventry, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Klatskin tumors

Biomarkers

  • Human equilibrative nucleoside transporter 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved